Risk-adjusted parity means FDA will direct its limited resources to surveillance
inspections that are most likely to achieve the greatest public health impact. The
assessment model will include risk factors relating to the facility (e.g., the
compliance history) and to the type of drugs manufactured at the facility. This may
mean that some facilities are inspected more often than others. Parity means that a
foreign facility will be inspected at an equal frequency as a domestic facility, plus
or minus 20 percent, with comparable depth and rigor.